Intervention With n3 LC-PUFA-supplemented Yogurt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effective dosage of a n3-LC-PUFA intervention (with n3 LC-PUFA-enriched yoghurt) on the modulation of cardiovascular risk factors and inflammatory biomarkers were determined.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients

NCT01437930

Hypertriglyceridemia

COMPLETED NA

Changes in Blood Lipids After Long-term Consumption of n-3 LC-PUFA-Enriched Dairy Products

NCT00639041

Hypertriglyceridemia

COMPLETED NA

Yogurt for Prevention of Chronic Inflammation

NCT04149418

Obesity Inflammation

COMPLETED NA

Cardio Protective Properties of a Yogurt Enriched With Bioactive Lipids of Olive Oil Products

NCT02259205

Cardiovascular Diseases

UNKNOWN NA

Functional Yogurt Consumption and Its Effects on the Lipid Profile of Healthy Subjects

NCT06574711

Cardiovascular Diseases Apolipoproteins Food Preferences +4 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 150 mg/dL (1.7 mmol/L)) participated on the placebo-controlled, double-blind, parallel designed study.

The subjects consumed placebo yoghurt (1), or n3 LC-PUFA-enriched yoghurt (0.8 g n3 LC-PUFA/d (2), 3 g n3 LC-PUFA/d (3)) for 10 weeks.

Blood samples were taken at the beginning and at the end of the period.

Parameters:

* Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)
* Fatty acid distribution of plasma lipids (PL) and erythrocyte membranes (EM)
* Concentrations of eicosanoids (PGs, HETEs)
* Production of ex vivo stimulated cytokines by T cells
* SNPs in the CD36 genotype

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate Hypertriacylglycerolemic Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

n3 long chain polyunsaturated fatty acids

Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hypertriacylglycerolemic subjects (TAG: ≥ 150 mg/dl (1.7 mmol/l))

Exclusion Criteria

* patients receiving blood-diluting and lipid-lowering medications or glucocorticoids
* patients suffering from gastrointestinal or metabolic diseases (e.g., diabetes mellitus, hyper- and hypothyroidism) and hypercholesteremic patients with familial previous impacts
* patients taking dietary supplements (e.g., fish oil capsules, vitamin E) or having either known allergies or foodstuff indigestibility

Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No